Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners (“Metalmark”), for the acquisition of its approximate 25% stake in Octomera LLC (“Octomera”), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera’s cell processing services, for the three calendar years 2025-2027, along with a portion of the proceeds attributable to Octomera’s cell processing services should there be a change of control in the next 10 years.
https://www.globenewswire.com/news-release/2024/01/31/2821239/24226/en/Orgenesis-Acquires-Control-of-Octomera-with-the-Goal-of-Progressing-its-Decentralized-Immuno-Oncology-Portfolio-to-Clinic.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.